For the treatment of chronic obstructive pulmonary disease of a chronic nature, the innovative medicine āOnbrez Breezhalerā was developed and tested for safety, the photo of which is presented below.
general characteristics
This medicine is produced by the Swiss company AG Novartis. There are two dosages (0.300 mg and 0.150 mg each) of the medicine āOnbrez Brizkhalerā. The description of the drug characterizes it as a white powder for inhalation, which is packaged in capsules.
This is a sympathomimetic inhalation agent used to treat obstructive diseases of the respiratory system. It is referred to as beta2-adrenostimulator selective action.
Larger-dose hard gelatine capsules of the third size have a transparent, colorless lid and trunk. The company logo is located on the upper part of the black paint, which is located below the black strip, on the bottom of the capsule contains the designation "IDL 150", which is located above the black strip.
In capsules of gelatine hard third-size smaller doses, there is a transparent, colorless lid and trunk. The company logo is painted on the upper half with blue paint, which is located below the blue strip, and on the bottom of the capsule contains the blue inscription "IDL 300", which is located above the blue strip.
Structure
One capsule contains 0.194 mg of indacaterol maleate for a lower dose and 0.389 mg for a larger dosage. An auxiliary component in the form of milk sugar serves as a filler, with its help adjust the mass of the contents.
Complicated is the Onbrez Breezhaler capsule shell composition, and the instructions include a list of all the ingredients. A lower dose coating is formed by shellac, gelatin, ferric oxide of black and trivalent black color, pure water, propylene glycol.
A larger dosage capsule shell includes slightly different ingredients. The coating is formed by shellac, gelatin, ferrous oxide of black and trivalent black color, pure aqueous medium, propylene glycol, blue diamond pigment, titanium dioxide.
Mechanism of action
Onbrez Breezhaler Medication Instructions for use describe the effect of the active ingredient indacaterol, which, as a chemical ligand, increases the response of beta2-adrenergic receptors. This pharmacological effect occurs due to the activation of the adenylcyclase enzyme inside the cells, in which the transition of adenosine triphosphate molecules to the cyclic 3 ', 5'-adenosine monophosphate is accelerated.
An increase in the last component causes a weakening of the smooth muscles in the bronchi. Indacaterol is highly active against beta2 receptors. Its selectivity is similar to that of formoterol.
Onbrez Breezhaler capsules, when administered by inhalation, exhibit a local bronchodilator effect in the respiratory system.
Its role is interconnected with the reduction of overstretching of the pulmonary walls in the middle or severe condition of obstructive disease, in a static and dynamic body position.
A single daily administration leads to a permanent significant improvement in respiratory performance. The active substance begins to act quickly and after 10 minutes its activity is manifested. This is much more effective than the effect of salbutamol at a dose of 0.200 mg or salmeterol / fluticasone at a dosage of 0.050 / 0.500 mg. The maximum activity of indacaterol is possible after 3-4 hours from the introduction of inhalation. Morning or evening use of the drug does not change its bronchodilator effect.
What heals
The medicine āOnbrez Breezhalerā, the instructions for use, advises patients with chronic obstructive pulmonary disease to use for supporting bronchodilation therapy of obstructive changes in the respiratory system. As a result of this disease, airflow is limited, the volume of air inhaled decreases, shortness of breath develops. The initial stage of the disease can be determined by coughing, sputum production, shortness of breath, and hoarseness during exercise.
How to use
For the Onbrez Brizkhaler medication, the methods of application and doses for adults are described in the instructions. Usually, doctors recommend one daily inhalation with the contents of one capsule with a dosage of 0.150 mg. The procedure is carried out using an inhaler or brihaler, it goes as a supplement to the medicine. The dosage can be increased only for medical purposes.
In severe lung obstruction, one inhalation per day is carried out with a capsule with a dose of 0.300 mg. The procedure is carried out using a brihaler. The maximum daily amount of medication is equal to 0.300 mg.
Onbrez Breezhaler medicines The instructions for use do not include dosage review requirements for elderly patients. Inhalations are not suitable for children, they are prescribed only after 18 years of age.
If the disease is combined with a malfunction of hepatic and renal functioning in mild or moderate form, then dosage adjustment is not carried out. With severe violations of the above organs do not carry out drug therapy.
For the medicine āOnbrez Breezhalerā, the methods of use are reduced only to the inhalation administration of the same company with a breezhaler. The capsule preparation is not suitable for swallowing. It must be used daily at a specific time period. If there is a break in treatment, then the subsequent administration is carried out at the set hours of the next day.
A device for inhalation and contour packaging containing capsules with powdered contents is enclosed in each pack of Onbrez Breezhaler. The medicine is equipped with a mouthpiece, a screen, a cap, a base and a button for a piercing device.
Before carrying out the manipulation, the cap is removed from the inhaler. To open the device, hold its lower part, then deflect the mouthpiece in the direction.
One capsule is taken out of the package, hands should be dry. Then it is inserted into the inhaler, putting in the designated area. Do not put the medicine inside the mouthpiece. The device closes with the appearance of a characteristic click.
The next step is to pierce the capsule. To do this, in a vertical position, one-time single pressing of two buttons for piercing is carried out. Usually a clicking sound is heard, which indicates a puncture of the capsule coating. Then press both buttons on the inhaler device.
The device is considered ready for manipulation and can be used. At the beginning of application, before introducing the mouthpiece into the mouth, the patient exhales air deeply. Then he puts the tube into the oral cavity, holding it with tightly compressed lips. They hold the breezhaler with one upper limb and carry out quick, uniform and deep inhalation of air. Do not touch the buttons of the piercing equipment.
During the manipulation, a characteristic rattling is heard, which is obtained when the shell is rotated and the contents are subsequently sprayed. The patient has a taste of sweet in the oral cavity. The absence of the desired sound signal requires the printing of an inhaler to check the capsule. It is possible that it will get stuck in the place of implementation. If a malfunction occurs, the capsule is removed by lightly tapping the base of the device. Do not re-press the side buttons. With a few piercing capsules, they can break.
During inhalation, a characteristic sound may occur, in this state the patient holds his breath for the time necessary to pull the mouthpiece out of the mouth. Only then air is exhaled. This is to prevent discomfort. Never blow into the handset of the device.
To check for the presence of powder inside the capsule, a person should lift the cap and look into the inhaler. When it is seen that there are a lot of capsule contents, they close the device and repeat all the above points in order to prepare it for manipulation. To the capsule is completely released, one or two injections of the drug are enough.
Inhalation can provoke a sharp attack of coughing. The reason for this condition is to receive a full dose of the drug. Sometimes a small amount of powder from the capsule may enter the oral cavity. Both violations should not cause excitement.
After inhalation, the patient needs to open the device, for this the mouthpiece is rejected, the shell of the empty capsule is removed and thrown away. Then lower the tube for the mouth and close the lid. It is forbidden to throw an empty capsule inside the device, rinse and unwind it.
When using new packaging, do not use the old inhaler. Only a dry place is suitable for storing packaging with the appliance and blisters.
For the Onbrez Brizkhaler medicine, the instruction recommends keeping a record of the performed manipulations using the calendar for marks, which is applied to the inner surface of the pack. When filling it out, a person will remember that the next inhalation is necessary.
To clean the instrument weekly, wipe the surface of the outer and inner mouthpiece using a clean, dry cloth. Do not use cleaning fluid. All parts of the inhaler must be dry.
Treatment features
Medicines "Onbrez Brizkhaler" instruction for use does not contain recommendations for use in patients with asthma. This is explained by the lack of information that would prove the effectiveness and safe introduction of such people.
Inhalation may be accompanied by increased sensitivity. If there are allergic processes associated with difficult breathing or swallowing, swelling of the tongue, lips and facial part of the head, rash in the form of urticaria, treatment should be abandoned and opposite measures should be taken.
Carrying out inhalation with a medication can provoke a spasm of the bronchi of a paradoxical type, which carries a danger to the patient's life. The slightest signs cause an urgent withdrawal of the medication and the use of the medicine to eliminate the attack.
The drug āOnbrez Brizkhalerā is able to aggravate the course of the disease, which is why it is not used as urgent measures in the initial stages of acute bronchospasm. If the condition of a patient with pulmonary obstruction as a result of inhalation of a drug worsens, a second assessment of the patient's well-being and method of treatment is carried out. Exceeding the maximum daily dosage is simply unacceptable.
If a severe attack has developed (obstructive and asthmatic), then the patient requires urgent hospitalization and resuscitation. Intensive care should begin as early as possible. For medical treatment, the introduction of adrenaline, corticosteroids, aminophylline is suitable.
A medication in the form of inhalations with the recommended dosage often does not contribute to a significant effect on the cardiovascular system, its effect is similar to substances that cause the response of beta2-adrenergic receptors. It is very carefully necessary to carry out manipulations for people with myocardial and vascular diseases, including coronary insufficiency, heart rhythm changes and high blood pressure, convulsive seizures and thyrotoxicosis. Caution is also necessary in case of an non-identical response to the influence of substances that cause the response of beta2-adrenergic receptor elements.
The medicine is able to significantly reduce the level of potassium ions in the blood, thereby causing the development of harmful processes in the work of the heart and blood vessels. Such a decrease in K + in plasma is considered temporary, not requiring its replenishment. In severe forms of bronchial obstruction and hypokalemia, a lack of oxygen develops. Treatment of hypoxia can lead to cardiac arrhythmia.
Inhaled administration of a high dose of the drug sometimes increases the glucose level in the blood. In this regard, careful monitoring of plasma sugar concentration for people with diabetes is recommended. To protect yourself from hyperglycemia, you should not use the medication often in high doses.
The opinion of experts on the Onbrez Brizkhaler medication shows poor compatibility of the drug and agonists of beta2-adrenergic receptor sites with a long exposure.
With this tool, only obstructive changes in the respiratory system in chronic form are treated. With inappropriate use of the medication, for example, with asthma of a bronchial type, there is a danger of the appearance of complex reactions in which the patient is hospitalized and inubated.
There are no clinical data that would characterize the effect of indacaterol on the process of bearing a child in the presence of chronic pulmonary obstruction. What potential effect it has on the human body is unknown. Women in position should be treated with this drug when it is necessary to obtain the expected benefit for the mother's body, which exceeds the possible danger to the unborn child. Like other beta2-adrenoreceptor agonists, the drug relaxes the smooth muscles in the uterus, which affects the strength of labor.
There is also no information about the ingestion of indacaterol or its metabolites in the composition of breast milk. There is evidence of the ingestion of active substances, as well as beta2-adrenergic inhalants, into the mammary glands, which makes it necessary to cancel the Onbrez Breezhaler medication during breastfeeding.
Under the influence of the drug, there is no change in male and female fertility, which is proved by studies of the reproductive system.
The drug is able to affect the management of transport or work with complex mechanisms, as it causes dizziness and impaired attention.
Who should not be used
The medicine āOnbrez Breezhalerā does not recommend the use of the drug with excessive sensitivity to the active ingredient, milk sugar or other additional components.
Inhalation is contraindicated in children under the age of 18 years. They are not given to patients suffering from Lapp-lactase deficiency, galactosemia, hereditary intolerance to milk sugar and galactose molecules.
Means "Onbrez Breezhaler": reviews of doctors
He is considered one of the newest medications for basic use in obstructive pulmonary disease. There is ample evidence of the effective and safe use of indacaterol. This tool is included in the GOLD program, which contains international recommendations for the treatment of chronic obstructive pulmonary disease.
Clinical trials of indacaterol were conducted with the participation of about 10,000 patients suffering from such a disease. It has been established that the active substance has a significant superiority in activity over pacifiers and other modern bronchodilators for the basic treatment of COPD.
On the medicine ā Onbrez Brizkhalerā, the reviews of doctors testify to its ultra-long action with a single daily intake. The drug provides fast bronchodilator efficacy five minutes after the end of the manipulation.
Also, for the Onbrez Breezhaler tool, reviews indicate a decrease in the frequency of deterioration in patients with obstruction of the lungs. With an exacerbation of the condition, the attack progresses rapidly, the patient is put in a hospital, and death can occur. Hospitalization is expensive.
Being a modern drug for the treatment of COPD, its active substance enters the lungs by inhalation during inhalation, which is carried out with a handheld device. The medicine causes relaxation of the smooth muscles in the bronchi, which contributes to their rapid expansion. Such high efficiency reduces the symptoms of the disease. So you can get rid of shortness of breath after 30 days from the start of manipulation. That is why the Onbrez Breezhaler capsules deserve positive reviews. Using the drug allows a sick person to be active and lead a normal and fulfilling life.
Patient opinion
On the Onbrez Breezhaler tool, reviews of people with chronic obstructive pulmonary disease of the lungs prove the effectiveness of inhalation. After 5 days of use, many patients noticed a decrease in shortness of breath, and after a course of treatment, people began to withstand the load, almost without suffocation.
You can hear negative reviews on the Onbrez Breezhaler capsules.They are associated with the appearance in some patients of clinically significant cardiovascular effects. These include an increased heart rate and high blood pressure. In this case, cancellation of treatment with this agent is required.
Analogs
The drug āOnbrez Breezhalerā is the head of the rating of bronchodilator drugs of basic action. It has better efficacy compared to salmeterol, formoterol and tiotropium drugs.
Ā«Ā» . , . 0,018 . 30 , .
Ā«Ā» . 0,025 0,050 . , 2- .
Ī²2- Ā«Ā» , . , , .